HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you should know is Delcath Systems, Inc. (DCTH). With promising liver cancer treatments in late-stage development (Phase 3 clinical trials) and a new European licensing deal for its CHEMOSAT® product, there is a lot to intrigue potential investors. With awareness among investors just starting to increase, we believe the Company not reached a proper market valuation.
An interventional oncology company focused on treating liver cancers with upside potential, Delcath Systems, Inc. (DCTH)(Market Cap: $3.215M, Share Price: $0.2880), is an interventional oncology company focused on treating liver cancers. In 2018, the Company amended its Phase 3 clinical trial in ocular melanoma liver metastases, raised $7 million via a right offering, secured a seven-year licensing agreement in Europe, and had data published in European Radiology among several other milestones. In 2019, the company is seeking to complete enrollment in its ocular melanoma liver metastases US registration trial.
Recently, DCTH announced they've received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. According to the World Health Organization, liver and bile duct cancers account for over 10,000 deaths in Brazil annually.
This comes after DCTH entered a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
DCTH also announced the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.
Consider researching DCTH soon.
Viking Therapeutics, Inc. (VKTX) (Market Cap: $626.703M, Share Price: $8.77) Chief Executive Officer, Brian Lian, recently delivered a corporate presentation at the 11th Annual Biotech Showcase™.
MannKind Corporation (MNKD) (Market Cap: $273.808M, Share Price: $1.47) announced a direct purchase program to help those with diabetes obtain the company's inhaled insulin, Afrezza, for as little as $4 a day. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
ImmunoGen, Inc. (IMGN) (Market Cap: $833.419M, Share Price: $5.59) recently reported a loss of $40.8 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss of 28 cents per share.
Aphria, Inc. (APHA) (Market Cap: $2.519B, Share Price: $10.15) said a special committee has concluded a review of the September acquisition of Latam Holdings Inc. and found conflicts of interest for some of its board members. The committee did, however, find that the price paid was within an ''acceptable'' range compared with comparable deals done by its competitors, albeit near the high end of that range. The market has reacted favorably to their news.
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC
View source version on accesswire.com: